Wang, Haohua
Zhang, Xiang
Leng, Boyu
Zhu, Kunli
Jiang, Shumei
Feng, Rui
Dou, Xue
Shi, Fang
Xu, Lei
Yue, Jinbo
Funding for this research was provided by:
National Natural Science Foundation of China (82272753)
Natural Science Foundation of Shandong Province (ZR2021LZL002)
Bethune Cancer Radiotherapy Translational Medicine Research Fund (flzh202103)
Article History
Received: 14 March 2024
Accepted: 12 August 2024
First Online: 12 September 2024
Declarations
:
: The Ethics Committee of the Affiliated Cancer Hospital of Shandong First Medical University approved the final protocol (Grant No. SDZLEC2023-390-02) in accordance with the Declaration of Helsinki and GCP principles. Formal approval is required for any change to the protocol that affects the conduct, patient benefit or safety of the trial. Patients will provide written informed consent after receiving a thorough explanation of the rationale, benefits and potential side effects. The trial will adhere to local regulations (clinicaltrail.gov identifier: NCT06246344).
: Not applicable.
: The authors declare no competing interests.